Senescent-cell-targeted delivery

Senescent-cell-targeted delivery decreases predicted adverse effects in silico (Zero predicted adverse effects).

“Exhaustive optimization (98,301 designs) shows that only senescent-cell-targeted delivery reaches zero predicted adverse effects, that neither systemic nor platelet-sparing PROTAC delivery does”

In silicoExhaustive optimization using illustrative heuristic per-node efficacy weights; not therapeutically validated

Localization, not selectivity: a causal node–cell–outcome framework for designing senescent-cell-directed senotherapeutics, with an application to inflammaging

Zenodo (CERN European Organization for Nuclear Research)·30 Jul 2026Preprint